I. Purpose.................................................................................................................. 1
II. Requesting a consult .......................................................................................... 1
III. General rules governing a request for a consult ................................................. 2
IV. Routing a request for a refuse to review (RTR)/refuse to file (RTF) assessment ....... 2
V. Routing a request for ONADE’s Office of the Director (HFV-100) ................. 3
VI. Routing a request for a chemistry, manufacturing, and controls consult (HFV-140). 3
VII. Routing a request for a human food safety consult (HFV-150) ....................... 4
VIII. Routing a request for an environmental impact consult (HFV-162) ............... 5
IX. Routing a request for a statistical consult (HFV-163 and HFV-164) ............... 6
X. Routing a request for a pharmacokinetics consult (HFV-166) ......................... 6
XI. Routing a request for a target animal division (TAD) consult ............................ 6
XII. Routing a request for a consult from the Quality Assurance Team (HFV-184) ... 8
XIII. Routing a request to the Project Management Teams (HFV-186 and HFV-187) ... 8
XIV. Routing labeling consult requests .................................................................... 8
XV. Routing a request to the Division of Veterinary Product Safety (HFV-240) ....... 9
XVI. References ...................................................................................................... 9
XVII. Version history .............................................................................................. 10

I. PURPOSE

This document describes the Office of New Animal Drug Evaluation’s (ONADE’s) standard procedures for routing a request for a consulting review (consult) of an investigational new animal drug (INAD) file, a generic investigational new animal drug (JINAD) file, an abbreviated new animal drug application (ANADA), a new animal drug application (NADA), or a veterinary master file (VMF) submission.

II. REQUESTING A CONSULT

Following the initial determination that a submission is ready to begin evaluation for review, the primary reviewer (PR) assesses what consults they need and routes the submission to the appropriate office, division(s) or team(s) for review. Consult packages are created and routed to the appropriate office, division or team using the ONADE Consult Request workflow in Appian. Detailed instructions on how to use the ONADE Consult Request workflow in Appian are in the Appian User Guide located on the Electronic Document Submission and Review (EDSR) page in SharePoint.

(Internal information redacted.)
III. GENERAL RULES GOVERNING A REQUEST FOR A CONSULT

The following guidelines are applicable to consulting a review:

A. When to Prepare the Request

The PR should keep in mind the current ONADE timelines so that the consulting reviewer(s) receiving the request has adequate time to perform the review. The request for a consult should be sent to consulting divisions/teams within five days after the submission is logged into our Submission Tracking and Reporting System (STARS) database.

B. How to Request a Consult

To request a consult, the PR should complete the "ONADE Consult Request" workflow in Appian. In the “Instructions for Consulting Reviewer” section of the template, clearly indicate what the consulting reviewer should review within the submission. The template contains a text box with a 12,500-character limit and does not allow for formatted text or tables. The instructions in the template box should be brief and if additional information or tables need to be communicated, they should be sent directly by email to the reviewer once assigned. The Create Consult Request workflow will create the appropriate consult package and direct it to the selected division/team unassigned list. Appian will also generate a notification email that is sent to the division/team point of contact notifying them that a new consult has been created and needs to be assigned in STARS. To determine who is receiving the consulting review request, refer to the ‘Consulting Review Points of Contact’ document located on the Office Templates page in SharePoint.

C. How to Request a Consult for Linked Submissions

When a PR receives a linked submission that requires a consult, only the lead submission should be consulted. You can determine what submissions are linked by checking the Submission Location and Status screen in STARS Web, which has a tab labeled “Linked”. This tab contains the lead submission ID and all linked submissions associated with it.

D. How to Request a Consult for an Amendment

Consults for amendments are separate from consults for parent submissions. Therefore, consults for amendments must be requested separately in Appian. The PR may choose to include the parent submission number and assigned consulting reviewer in the request for convenience in the ‘Instructions for Consulting Reviewer’. Refer to P&P 1243.3026 for more information regarding amending STARS submissions.

IV. ROUTING A REQUEST FOR A REFUSE TO REVIEW (RTR)/REFUSE TO FILE (RTF) ASSESSMENT

To request a RTR/RTF consulting review for a submission, follow the procedures outlined in P&P 1243.3100. The RTR assessment is for (J)INAD P submissions and the
RTF assessment is for original or supplemental (A)NADAs A and C applications containing data, excluding submissions received by the Division of Manufacturing Technologies.

V. ROUTING A REQUEST FOR ONADE’S OFFICE OF THE DIRECTOR (HFV-100)

When requesting a consult using the Appian Consult Request workflow, you must select “Office” for the Review Level, and then select “ONADE”. Some examples when official consults might be necessary are to request feedback from the ONADE Policy Team for legal issues raised by a potential applicant in a meeting request or when feedback from a Senior Scientist is needed regarding complex bioequivalence issues. However, the reviewer should first discuss with the Policy Team or Senior Scientist prior to creating the official consult in Appian.

Requests for a consult from the Office of the Director (HFV-100) include:

- Policy Team (HFV-108)
- Senior Scientist Team

When requesting a consult for the Animal Bioengineering and Cellular Therapies Team (HFV-106) using the Appian Consult Request workflow, you must select “Division” or “Team” for the Review Level, and then select “ONADE”.

- Animal Bioengineering and Cellular Therapies Team (HFV-106)

VI. ROUTING A REQUEST FOR A CHEMISTRY, MANUFACTURING, AND CONTROLS CONSULT (HFV-140)

A request for a Chemistry, Manufacturing, and Controls (CMC) consult is routed to the appropriate team in the Division of Manufacturing Technologies (HFV-140) as follows:

A. NADAs and INADs

- If the submission pertains to a major species for a medicated article or feed (i.e., Type A medicated article, Type B medicated feed, and Type C medicated feed) or a topical product, the submission should be routed to the Feed/Topical Team (HFV-141).

- If the submission pertains to a sterile drug product (i.e., injectable or ophthalmic products), the submission should be routed to the Antimicrobial Team (HFV-142).

- If the submission pertains to an oral dosage form (i.e., tablet, oral solution, etc.), the submission should be routed to the Chemotherapeutics Team (HFV-143).

- If the submission pertains to a biological/biotechnological or competitive exclusion derived drug product, a Minor Use Minor Species drug product, a soluble powder (major and minor species), non-sterile injectable (i.e., euthanasia products), or inhalant the submission should be routed to the Biotherapeutics Team (HFV-144).
B. ANADAs and JINADs

- If the submission pertains to a sterile injectable drug product, the submission should be routed to Generic Review Team I (HFV-145).

- If the submission pertains to an oral dosage form (i.e., tablet, capsule, oral solution, etc.), or a topical drug (i.e., opthalmic, otic, dermatologic), the submission should be routed to Generic Review Team II (HFV-146).

- If the submission pertains to a major species for a medicated article feed (i.e., Type A medicated article, Type B medicated feed, and Type C medicated feed) or a soluble powder, the submission should be routed to Generic Review Team III (HFV-147).

C. Veterinary Master File, or Review of a (A)NADA or (J)INAD Specifically for the Review of a Veterinary Master File

- If the submission pertains to the review of a drug substance/API or Type II veterinary master file, the submission should be routed to the Drug Substance Matrix Review Team (HFV-148).

VII. ROUTING A REQUEST FOR A HUMAN FOOD SAFETY CONSULT (HFV-150)

If a new animal drug is intended for use in food-producing animals, the submission is sent for a consult to the Division of Human Food Safety (HFV-150).

A. Antimicrobial Resistance

If the submission contains antimicrobial resistance-related information (e.g., protocols, study reports, supporting literature, etc.) or is an application for new antimicrobial drugs or changes to previously approved antimicrobial drugs, send the request to the Microbial Food Safety Team (HFV-157).

B. Impact of Residues on Human Intestinal Flora

If the submission contains information addressing the potential impact of residues on human intestinal flora, send the request to the Microbial Food Safety Team (HFV-157).

C. Toxicology

If the submission contains toxicology-related information (e.g., general toxicology, genetic toxicology, and reproductive toxicology studies), send the request to the Toxicology Team (HFV-153).

D. Residue Chemistry

If the submission contains residue-related information (e.g., studies and summaries of studies pertaining to presence and identification of residues in edible tissues, metabolism studies in the target species, comparative metabolism studies in the toxicological species, residue depletion studies in the food-
producing animal, analytical methods for detection or identification of residues in the target animal, send the request for review to the Residue Chemistry Team (HFV-151). For ANADAs/JINADs where the generic new animal drug product is proposed for use in food-producing animals and no studies were performed (i.e., waived products), send the consult request to the Residue Chemistry Team (HFV-151).

E. Multiple Human Food Safety Components

For all non-Z submissions that contain information applicable to more than one team in HFV-150, send a single request for a consult to HFV-150. They will route it, as appropriate, within the division. This includes food-use authorizations.¹

For all Z submissions (unless specifically directed to one team), route four separate requests to HFV-150 (e.g., A1, B1, C1, and D1) – one to HFV-151 (residue chemistry), one to HFV-153 (toxicology), and two to HFV-157 (for impact of residues on human intestinal flora and antimicrobial resistance). They will return requests to the PR as needed.

F. User Safety and Residual Solvents

User safety and residual solvent consult requests should not be automatically routed to HFV-150. The PR should examine this information themselves and request a consult, if needed. Refer to the information contained in the ONADE Scientific Resource Document 1243.130.001 on the human user safety assessment.

VIII. ROUTING A REQUEST FOR AN ENVIRONMENTAL IMPACT CONSULT (HFV-162)

If the submission contains information related to the environmental impact technical section or a request for categorical exclusion from preparing an environmental assessment, send the consult request to the Environmental Safety Team (HFV 162). Refer to information contained in P&P 1243.7220.

For ANADAs (full approval applications) where the Environmental Impact technical section has not been reviewed and found complete in a prior ANADA or JINAD within the previous 5 years, send the consult request to the Environmental Safety Team (HFV 162). For supplemental ANADAs (NF or NL²), refer to ONADE SOP for further instruction on the evaluation of categorical exclusion requests.

¹ Refer to P&P 1243.4040 and P&P 1243.4041 for more information regarding investigational food-use authorizations.
² Changes being effected Non-fee Labeling Supplements (NL) and Prior approval Labeling Supplements Non-Fee Labeling (NF) are described in P&P 1243.6020 and P&P 1243.6040.
IX. ROUTING A REQUEST FOR A STATISTICAL CONSULT (HFV-163, HFV-164 AND HFV-165)

If the submission contains statistical analysis information (i.e., protocol or data submissions), send the consult to the appropriate Biostatistics Team (HFV-163, HFV-164, or HFV-165).

- Biostatistics Team 1 (HFV-163):
  
  Drug/Study Types: antiparasitics in companion animals (from HFV-118), drugs for reproduction, weight control, and appetite stimulation; and drugs for endocrine (e.g. thyroid, diabetes), cardiovascular (blood pressure, heart), ophthalmic, hematology, and renal/urinary disorders. Team 1 also reviews animal bioengineering and cellular therapies in these indications, as well as environmental and human food safety studies.

- Biostatistics Team 2 (HFV-164):
  
  Drug/Study Types: antiparasitics in companion animals (from HFV-112), antiparasitics for production animals (except fish), and immunosuppressants; drugs for pain, epilepsy, and for neurological, dermatological, otic, and muscular disorders. Team 2 also reviews animal bioengineering and cellular therapies in the above indications.

- Biostatistics Team 3 (HFV-165):
  
  Drug/Study Types: generic drugs, antimicrobials (for respiratory [BRD, SRD] and other infections), and antivirals; drugs for cancer, pyrexia, gastrointestinal disorders (e.g., ulcers, nausea, vomiting), and respiratory (not microbial) disorders; and drugs to induce euthanasia or sedation. Team 3 also reviews production drugs and fish drugs (all indications), and animal bioengineering and cellular therapies that fall under the above indications.

X. ROUTING A REQUEST FOR A PHARMACOKINETICS CONSULT (HFV-166)

For INADs/NADAs, if a submission contains information pertaining to the pharmacokinetics (PK) of the new animal drug (e.g., PK studies, proposed plasma drug concentration sampling times), a PK consult may be requested. For JINADs/ANADAs, if a submission contains information that raises concerns with drug pharmacokinetics (i.e., bioequivalence study design for a long acting new animal drug, the effect of indwelling catheters and catheter flushing on plasma samples), a PK consult may be requested. Refer to the information contained in ONADE SOP for more details. Send the consult request to the Clinical Pharmacology Team (HFV-166).

XI. ROUTING A REQUEST FOR A TARGET ANIMAL DIVISION (TAD) CONSULT

The PR sends requests for consults from a TAD reviewer for various types of submissions when needed. Some examples for when a consult might be needed...
would be for requests to attend sponsor meetings, CMC supplements with labeling, end game meetings, etc.

A. Companion Animal and Wildlife Products are Reviewed by the Division of Therapeutic Drugs for Non-Food Animals (HFV-110).

1. Team 1 (HFV-112) reviews anti-parasitics (split with HFV-118), endocrine, dermatologic, respiratory drugs, reproductive drugs, and euthanasia agents.

2. Team 2 (HFV-114) reviews analgesics/anti-inflammatory drugs (osteoarthritis and disease-modifying osteoarthritis drugs), cellular therapy agents, blood products, antimicrobials, and most equine drugs.

3. Team 3 (HFV-116) reviews anesthetics, sedatives, analgesics (Post-operative pain), gastrointestinal, oncologic, recombinant technology, and renal/urinary drugs.

4. Team 4 (HFV-118) reviews anti-parasitics (split with HFV-112), neurology, cardiac, otic, ophthalmic, anti-virals, and behavior drugs as well as drugs for wildlife.

B. Production Drugs and Combination New Animal Drug Applications Seeking Approval Under the Animal Drug Availability Act (ADAA) are Reviewed by the Division of Production Drugs (HFV-120).

1. Ruminant Drugs Team (HFV-126)

2. Swine and Poultry Drugs Team (HFV-128)

C. Food Animal Therapeutic Drugs, Aquaculture Products, and Superovulation Products are Reviewed by the Division of Therapeutic Drugs for Food Animals (HFV-130).

1. Aquaculture Drugs Team (HFV-131)

2. Antimicrobial Drugs Team (HFV-133)

3. Antiparasitic and Physiologic Drugs Team (HFV-135)

D. Abbreviated New Animal (Generic) Drugs are Reviewed by the Division of Generic Animal Drugs (DGAD) (HFV-170)

The DGAD has four multi-disciplinary teams (HFV-171, 172, 173, and 174), consisting of veterinarians, chemists, pharmacists/pharmacologists and biologists. The DGAD relies heavily on internal consults for all aspects of its JINAD/ANADA bioequivalence studies (data quality, clinical veterinary data, bioanalytical methods, dissolution methods).

1. Review Team 1 (HFV-171)

3 Refer to P&P 1243.3051 regarding the End Game
2. Review Team 2 (HFV-172)
3. Review Team 3 (HFV-173)
4. Review Team 4 (HFV-174)

XII. ROUTING A REQUEST FOR A CONSULT FROM THE QUALITY ASSURANCE TEAM (HFV-184)

- If a Quality Control review for documents that are signed by the Center Director and/or Office Director (e.g., RTR/RTF letters, approval packages and investigational food-use authorizations) is needed from the Quality Assurance Team, refer to the procedures in P&P 1243.3210.

- If a Quality Assurance Study Review is needed for the evaluation of data quality, then a consult from the Quality Assurance Team should be requested according to the procedures in P&P 1243.3215.

XIII. ROUTING A REQUEST TO THE PROJECT MANAGEMENT TEAMS (HFV-186 AND HFV-187)

For INAD/NADA submissions, there are infrequent situations that a consult may be requested from the project management teams. An example of a situation would be to request that a project manager (PM) attend a pre-INAD meeting to go over the new animal drug approval process with the sponsor. If a project management consult is needed, check the SharePoint list showing which PMs are assigned to which sponsors to determine which PM team should receive the consult. If this cannot be determined from the information in SharePoint, contact one of the PM team leaders or send the consult to HFV-180.

XIV. ROUTING LABELING CONSULT REQUESTS

For review of labeling changes in manufacturing supplements, the appropriate target animal division in Section XI should be consulted based on the information submitted in the A(NADA) application. Refer to the information contained in P&P 1243.6030 for information on manufacturing supplements.

For all INAD/JINAD labeling (M) submissions, original (A)NADAs and B1 supplements the PR sends requests for labeling consults to:

- Post-Approval Review Team (HFV-216) in the Office of Surveillance and Compliance (OSC)'s Division of Surveillance for all new animal drug labels (except Type A medicated articles and Type B and C medicated feeds). For JINAD/ANADAs, consult all JINAD G (general correspondence for labeling) or M

---

4 Internal information redacted.
5 Refer to P&P 1243.4080 for information regarding the Labeling Technical Section
6 Refer to P&Ps 1243.6020 and 6040 for information on the process for NL and NF submissions
7 A B1 supplement is one in which safety and/or effectiveness was evaluated. An example of an ANADA B1 supplement would be when the sponsor of an ANADA adds an indication or species that is not approved for the reference listed new animal drug product.
(Labeling technical section) submissions to the Post-Approval Review Team (HFV-216) for proprietary name and/or trade dress review, as applicable.

- If the labeling is for an original or B1 supplemental NADA Type A medicated articles and/or Types B and C medicated feeds, send the request for a consult to the Medicated Feeds Team in the Division of Animal Feeds (HFV-226).
  - A consult to the Medicated Feeds Team (HFV-226) is typically not required for ANADA Type A medicated articles or Types B and C medicated feeds and are requested in very limited circumstances. Consult with your TL, if you think that a consult to HFV-226 may be necessary.
- The appropriate team in the Division of Manufacturing Technologies as stated in Section IV above.  
- Division of Human Food Safety (if it is a new animal drug used in food-producing animals)

**XV. ROUTING A REQUEST TO THE DIVISION OF VETERINARY PRODUCT SAFETY (HFV-240)**

To request an Adverse Drug Experience (ADE) and Product Defect (PD) review, the PR should route a consult to the Division of Veterinary Product Safety (DVPS). A Brief Adverse Event Review (typically takes 21-30 days) or Standard Adverse Event Review (typically takes 60-90 days) can be requested.

If a generic sponsor requests to open a JINAD for a RLNAD that is no longer marketed, create a “Q” submission under the RLNAD using the “ONADE Create Q Submission” workflow in Appian. Send a request to DVPS to confirm that it was not withdrawn from the market due to safety or effectiveness reasons. See P&P 1243.3250 for more information on Q submissions.

The consult is created by completing the DVPS ADE and PD consult request form. The consults are not requested through Appian. The consult request form and instructions are found on the ONADE Forms SharePoint site:

Internal information redacted.

**XVI. REFERENCES**

CVM Program Policies and Procedure Manual

1243.3026 – Amending and Resetting the Clock on Submission Tracking and Reporting System (STARS) Submissions

Internal information redacted.

---

8 A consult to the Division of Manufacturing Technologies should always be requested for JINAD ‘M’ submissions, even if the CMC section has already been determined to be complete.
1243.3210 – Requesting a Quality Control Review from the Quality Assurance Team

1243.3215 – Requesting a Quality Assurance Study Review from the Quality Assurance Team

1243.3250 – Q-Submissions Agency-Initiated Actions

1243.4040 – Investigational Food-Use Authorizations: The Role of the Target Animal Division Reviewer

1243.4041 – Investigational Food-Use Authorizations: The Role of the Division of Human Food Safety Reviewer

1243.4080 – Labeling and All Other Information Technical Sections (Minor Technical Section or M Submissions)


1243.6030 – Review of Labeling Changes in Manufacturing Supplements

1243.6040 – Review of (A)NADA 60-day and 180-day Non-Fee (NF) Prior Approval Labeling Supplements

1243.7220 – Processing Environmental Impact Submissions for New Animal Drugs

XVII. VERSION HISTORY

November 16, 2001 - Original version

December 19, 2007 – Version updated to remove sections now in the approval package P&P 1243.3800. Also reformatted and brought up to date regarding processing of labeling supplements.

November 2009 - The instructions for requesting a consulting review were updated to reflect current procedures and now include instructions regarding consults for ERAs.

August 31, 2012- The P&P was updated to include the routing of consults to the biostatistics teams and to reflect the changes due to the electronic environment.
November 2, 2012 – Updated to reflect that parent submissions do not need to be consulted with ERAs.

July 2, 2013 – Updated with additional division/team information, the use of an Outlook template to request consults, and to reflect the unified Center procedure for using Appian to return consults.

April 8, 2014 – Updated to reflect the Appian Create Consult workflow process.

June 13, 2014 – Updated to current format.

July 5, 2016 – Updated to current format and redacted internal information for internet version.

November 26, 2018 – Removed end-review amendment process and updated with current information.

January 17, 2019 – Updated references to reflect the P&P 1243.4090 for human user safety assessment is now a CVM ONADE Scientific Resource Document and is found on the ONADE Standard Operating Procedures and Resource Documents SharePoint page.

May 9, 2019 – Updated information on the teams within HFV-160 and HFV-170.